Piche ME, et al. - Researchers undertook an evaluation of the effect of 1-year treatment with the insulin sensitizer peroxisome proliferator-activated receptor (PPAR)-γ agonist rosiglitazone on exercise capacity and blood pressure (BP) response to exercise in men with coronary artery disease (CAD) and type 2 diabetes (T2D). As per the findings, insulin sensitizer rosiglitazone reported a beneficial effect on resting and BP response to exercise in men with CAD and T2D, particularly in those with an exaggerated BP response to exercise.